Pet Cancer Therapeutics Market – By Species, By Therapy, By Route of Administration, By Cancer Type – Global Forecast, 2025 to 2034

Pet Cancer Therapeutics Market Size

The global pet cancer therapeutics market size was valued at USD 477.1 million in 2024 and is estimated to grow at a CAGR of 9.7% from 2025 to 2034. The market has experienced rapid growth due to the rise in pet healthcare spendings and trend towards pet humanization.
 

For instance, the American Pet Products Association (APPA) National Pet Owners Survey estimated that about 66% of American households, approximately 87 million families, own pets, that includes about 65 million dogs and 46.5 million cats. Moreover, during the 2023 survey, an average expenditure of USD 37 billion was expected on veterinary care, and America’s growing concern for pets corresponded with an expansion in the market growth. This trend asserted a significant growth in the market.
 

Moreover, the rising cases of pet cancer coupled with demand for potential treatment methods has led to more advanced diagnostic and targeted therapies which has led to market growth. Increasing cancer rates within soaring pet populations with age has increased expenditure towards veterinary oncology to achieve better surgical outcomes. Additionally, pet owners being driven by improved veterinary medicine further the growth of the market as they seek quality life extending treatments for their pets.
 

Pet cancer therapeutics pertain to a spectrum of treatments designed to diagnose, manage, and treat cancers in pets, particularly dogs, cats, and other pet animals. These therapeutics include chemotherapy, targeted therapies, immunotherapies, and other combinations that target the reduction of the tumor size and symptoms while extending pet health.
 

Pet Cancer Therapeutics Market Trends

Advancements in veterinary oncology are boosting the market through development of new and innovative treatments focused on improving outcomes in pet cancer treatments.
 

• Developments such as precision therapies, advanced diagnostics, and immunotherapy are less invasive and lead to better survival outcomes for pets suffering from cancers. This growth is positively impacting the global market expansion.
   
• For instance, in October 2024, Calviri, a biotech company specialized in vaccines for dogs and humans cancer, initiated a clinical trial for an immunotherapy investigational vaccine for dogs with early stage hemangiosarcoma (HSA). The SOCH study is to determine if the “pre-made” vaccine with adjunctive surgery and chemotherapy can keep dogs with stage 1 or 2 HSA alive longer by having their immune system attack the cancer. This trial launch is aimed at making significant progress in canine cancer treatments.
   

Moreover, there are certain factors like high costs, regulatory hurdles, lack of specialized veterinary practitioners, and less awareness in low-income countries are expected to hinder the market growth.
 

Pet Cancer Therapeutics Market Analysis

Based on species, the global market is segmented into dogs, cats and other species. The dogs segment dominated the market and was valued at USD 402 million in 2024.
 

• Dogs are more frequently diagnosed with cancers such as lymphoma, osteosarcoma, and mammary tumors. This leads to an increasing demand for therapeutic treatments for dogs solidifying its position in the market.
   
• For instance, according to a statistic published by the Veterinary Cancer Society, around 47% of dogs suffer from cancer, especially those dogs above age ten. This statistic elevated awareness towards the increasing demand and prevalence of cancer treatments for dogs over ten years as well as increasing age expectational gap. The need for pet cancer therapeutics is expected to grow steadily in aging dogs.
   
• In addition, the emergence of early diagnosis and effective treatment has driven the growth in the market.
   
• Furthermore, the growing awareness among pet owners along with a specific treatment for dogs has also aided towards helping this segment remain the biggest in this market.
   
• There has been much research done in the field including the drugs which have been approved for lymphoma which is a widely common form of cancer in dogs. These include the Tanovea (rabacfosadine injection) that was approved by the U.S FDA in 2021. There are many other clinical trials taking place such as the Calviri, Inc's 2022 vaccine against canine cancer study which further emphasizes the growth of this sector.

Based on the therapy, the global pet cancer therapeutics market is segmented into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment accounted for the highest market share of 62.1% in 2024.
 

• Chemotherapy effectively targets and kill the cancer cells or inhibit their growth making it a preference as go-to treatment for most cancer including lymphoma and mast cell tumors.
   
• Since chemotherapy drugs are among the most potent in existence, achieving a recovery rate of more than 80% for conditions such as lymphoma is routine. This astonishing rate has been shown in dogs afflicted with cancer all over the world.
   
• Chemotherapy is one of the cornerstones of treatment in veterinary oncology and, with the increasing ownership of pets and subsequent awareness of animal health, the market opportunity continues to grow.
   

Based on the route of administration, the global pet cancer therapeutics market is segmented into oral and injection. The injection segment dominated the market in 2024 and is anticipated to reach USD 789 million by 2034.
 

• The use of injections arises from their ability to facilitate the administration of cancer treatment directly into the bloodstream or tumor.
   
• Injectable therapy including chemotherapy and immunotherapy agents expands to have increased absorption and targeting effect which has major advantages on many cancers seen in pets.
   
• These treatments are more favored for their precision and better control of side effects.
   
• As new injectable formulations are being developed, the need for injectable cancer therapeutics in veterinary practice is expected to remain strong, thus increasing the prominence of this segment in the market.
   

Based on cancer type, the global pet cancer therapeutics market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and other cancer types. The mast cell cancer segment is expected to grow at a 9.4% CAGR over the analysis period.
 

• The robust incidence of mast cell cancer can be explained by the high incidence of mast cell tumors in canines, especially within certain breeds such as Boxers, Bulldogs, and Retrievers.
   
• Pets are afflicted by a number of skin tumors, though mast cell tumors are the most common types of skin cancers found and often need prompt, effective treatment due to their aggressive nature.
   
• For instance, as reported by Morris Animal Foundation, about 16% to 21% of all skin tumors in pets consist elucidated mast cell tumors, which have different shapes and features. Their growth pattern differs also, with some growing slowly while others form diffuse lesions that are ulcerated and itchy.
   
• As a result, in combination with the proclivity of these tumors for malignancy and other complications, these factors have resulted in the mast cell cancers niche dominating the market.
   
• Their prevalence, along with the potential for malignancy and complications, has contributed to the dominance of the mast cell cancer segment in the market.

In 2024, the U.S. held a significant position in the North American pet cancer therapeutics market and projected to dominate throughout the forecast period with a CAGR of 9.3%.
 

• The U.S. leadership stemmed from the developed veterinary health system alongside high rates of pet ownership and growing consciousness regarding cancer therapy for pets.
   
• The country poses substantial resources in oncology surgery owing to the state-of-the-art technology, innovations, and diverse treatment modalities available such as chemotherapy, immunotherapy, and targeted therapy.
   
• In addition, the increasing instances of pet cancers in elderly pets is also a major factor contributing to the growth of these therapeutics.
   
• Furthermore, the existence of major veterinary pharmaceutical companies and animal health clinics services reinforced the position of the U.S. as a major factor in the development of the market in North America.
   

The pet cancer therapeutics market in Germany is estimated to grow at significant growth rate over the next few years.
 

• Germany’s market of cancer therapeutics for pets is expanding due to improved awareness of pet health, improvement in veterinary oncology, and growing pet ownership coupled with a greater need for specialized treatment.
   
• For example, Der Deutsche Heimtiermarkt 2021 reported that 47% of German households had pets, and there were altogether 34.7 million dogs, cats, small animals, and birds. The increase in pet ownership has created an awareness towards pet welfare, leading to increased spending on veterinary care and treatment of cancers.
   
• Since cancer is one of the prime causes of death for pet animals, this indicator points towards an increase in the demand for cancers diagnosis and treatments aids, which is further aids by the existing studies done in the country.
   

China held the prominent position in the Asia Pacific pet cancer therapeutics market during the analysis period.
 

• The growth of China can be linked with the increasing occurrence of pet cancer, growing concern among pet caregivers and vets addressing the issue, and improvement in veterinary techniques.
   
• Also, the strengthening of biotechnological companies in the country and the pet friendly policies of the government make the country more competitive for production in the veterinary drugs. Domestic companies innovation for affordable cancer treatment has further elevated the growth in the market.
   
• Furthermore, the growing awareness towards pet care and cancer treatment is enabling the need for advanced veterinary care in the country.
   
• Moreover, the market’s growth is further stemmed from the increasing demand for chemotherapy, immunotherapy and other oncological treatments for pets.
   

Brazil pet cancer therapeutics market is anticipated to witness high growth over the analysis timeframe in Latin America.
 

• Raising pet ownership trends and increasing awareness towards pet cancer treatment are encouraging advanced veterinary services in the country.
   
• Furthermore, increased acceptance towards innovative cancer interventions in pets, including chemotherapy, immunotherapy, and targeted therapies, is also fueling the market growth.
   
• Moreover, changes in the Brazilian veterinary healthcare system combined with more efficient cancer treatment medications are expected to improve the access to this treatment.
   
• Therefore, the aforementioned factors witnessed Brazil’s prominence in the Latin American market.
   

Saudi Arabia is anticipated to grow in the Middle East and African pet cancer therapeutics market.
 

• Saudi Arabia's urban population is increasingly owning pets due to wealth gain and is subsequently heightening the demand for advanced veterinary services.
   
• In addition, increasing awareness of pet health and cancer treatment, a growing number of pet owners are opting for specialized cancer treatments like chemotherapy and immunotherapy.
   
• Alongside, the growing investment in research and developments, the Brazilian veterinary healthcare infrastructure is also improving providing better access to advanced treatment.
   
• Thus, the aforementioned factors collectively turn Saudi Arabia into one of the leading markets for pet cancer therapeutics during the forecast period.
   

Pet Cancer Therapeutics Market Share

The market is highly competitive in nature due to the presence of key players. Currently, companies are strongly focusing on expanding their product portfolios by innovations in chemotherapy, immunotherapy, and targeted treatment. In addition, the market positions continue to be strengthened by further strategic partnerships, mergers and acquisitions, and investments in research and development. Also, the rising demand for modern treatments for pet cancer has escalated competition which in turn fosters the development of new therapeutics to address changing consumer needs.
 

Pet Cancer Therapeutics Market Companies

Few of the prominent players operating in the pet cancer therapeutics industry include:

• AB Science
• Boehringer Ingelheim International
• CureLab Oncology
• Dechra Pharmaceuticals
• Elanco Animal Health
• ELIAS Animal Health
• NovaVive
• Qbiotics
• Pfizer
• Torigen
• Vibrac
• Vivesto
• Zoetis
   

USPs of the companies

• Continuous R&D investment driving breakthrough in pet cancer treatments
   
• Providing affordable therapeutic options expanding accessibility to pet owners
   
• Entering collaborative agreements to expand the product innovations and accessibility to improve pet healthcare outcomes
   

Pet Cancer Therapeutics Industry News

• In August 2024, FidoCure, the flagship brand of One Health Company, received a patent from the US Patent and Trademark Office (USPTO) for an innovative targeted therapy and biomarker aimed at treating canine cancer. This novel treatment approach utilizes mutation profiling to more effectively manage bladder cancer in dogs. This advancement is expected to address the spurring demand for targeted treatments and precision medicine in veterinary oncology continues to rise.
   
• In July 2024, ELIAS Animal Health launched a new study to evaluate its adoptive T cell therapy, the ELIAS Cancer Immunotherapy (ECI). The study aimed to explore the combination of ECI with a novel adjuvant as a limb-sparing treatment for large-breed dogs diagnosed with appendicular osteosarcoma. This research marked a significant step toward advancing personalized cancer care in pets and is expected to contribute to the growing demand for novel therapies in the pet care industry.
   

The pet cancer therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Species

• Dogs
• Cats
• Other species

Market, By Therapy

• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Market, By Route of Administration

• Oral
• Injection

Market, By Cancer Type

• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE